Ernexa Therapeutics (ERNA) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $4.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | PMCB |
|---|---|---|
| Share price | $2.49 | $0.3974 |
| Market cap | $4.06M | $4.27M |
| 1-day change | +4.18% | -2.02% |
| EPS (TTM) | $-13.63 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $1.51 |
| 52-week low | $2.14 | $0.3339 |
| Distance from 52-week high | -96.52% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +1104.82% | — |
| Average volume | 472.81K | 205.72K |
| Shares outstanding | 1.63M | 10.74M |
| Employees | 5 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Healthcare · Biotechnology · 5 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Healthcare · Biotechnology · 2 employees
ERNA vs PMCB FAQ
Which is bigger, Ernexa Therapeutics or PharmaCyte Biotech?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $4.06M for Ernexa Therapeutics (ERNA).
Are Ernexa Therapeutics and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.